UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-KSB/A-1

(Mark One)



|x | ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ------------------------------------------------------------------------------

For the fiscal year ended December 31, 2006.



| ̈ | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|- | ----------------------------------------------------------------------------------

For the transition period from _____________ to __________

Commission file number 0-51492

Synova Healthcare Group, Inc.

(Name of small business issuer in its charter)



|                                                               |  |                                     
|-------------------------------------------------------------- |  | ------------------------------------
|Nevada                                                         |  | 91-1951171                          
|(State or other jurisdiction of incorporation or organization) |  | (I.R.S. Employer Identification No.)
|                                                               | 
|1400 North Providence Road, Suite 6010, Media, PA              |  | 19063                               
|(Address of principal executive offices)                       |  | (Zip Code)                          

Issuers telephone number: (610) 565-7080

Securities registered under Section 12(b) of the Exchange Act: None

Securities registered under Section 12(g) of the Exchange Act:

Common Stock, par value $.001 per share

(Title of class)

Check whether
the issuer is not required to file reports pursuant to Section 13 or 15(d) of the Exchange Act. ̈

Note  Checking the box above will not relieve any registrant required to file reports pursuant to Section 13 or 15(d) of the Exchange Act from
their obligations under those Sections.

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the
Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  x No ̈

Check if there is no
disclosure of delinquent filers in response to Item 405 of Regulation S-B contained in this form, and no disclosure will be contained, to the best of registrants knowledge, in definitive proxy or information statements incorporated by
reference in Part III of this Form 10-KSB or any amendment to this Form 10-KSB. ̈

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ̈No  x

The issuers net sales for its
most recent fiscal year were $187,970.

As of December 28, 2006, the aggregate market value of the voting and non-voting common equity held by
non-affiliates computed by reference to the closing price of such common equity, was $11,454,000.

As of February 22, 2007, the number of shares of
Common Stock outstanding was 33,228,398.

DOCUMENTS INCORPORATED BY REFERENCE

No documents are incorporated by reference into this Form 10-KSB.

Transitional Small Business Disclosure Format (check one): Yes ̈No  x





---

EXPLANATORY NOTE

This Amendment No. 1 on Form 10-KSB/A (Amendment No. 1) is being filed to amend the Annual Report on Form 10-KSB for the fiscal year ended December 31, 2006 (the Original Form
10-KSB), as filed by Synova Healthcare Group, Inc. with the Securities and Exchange Commission on February 26, 2007. Amendment No. 1 is being filed solely to correct a footnote in the beneficial ownership table in Item 11, and
no other changes are being made by this Amendment No. 1.

PART III

Item 11.Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

Security Ownership of Certain Beneficial Owners and Management

The following table sets forth certain information with respect to the beneficial ownership of our common stock as of February 22, 2007 by the following persons:



| |  |  | each of our directors;
| | - |  | ----------------------



| |  |  | each of the named executive officers;
| | - |  | -------------------------------------



| |  |  | each person known by us to be the beneficial owner of more than 5% of our outstanding common stock; and
| | - |  | -------------------------------------------------------------------------------------------------------



| |  |  | all of our executive officers and directors as a group.
| | - |  | -------------------------------------------------------

As of February 22, 2007, there were 33,228,398 shares of our common stock outstanding. Unless otherwise noted below, and subject to applicable community property laws, to our knowledge, each person has sole
voting and investment power over the shares shown as beneficially owned by them. The number of shares beneficially owned by each stockholder is determined under rules and regulations promulgated by the SEC. The information does not necessarily
indicate beneficial ownership for any other purpose. In computing the number of shares beneficially owned by a person and the percentage ownership of that person, shares of common stock subject to options, warrants or other convertible securities or
rights held by that person that are currently exercisable or exercisable within 60 days of February 22, 2007 are deemed to be presently outstanding. These shares, however, are not deemed outstanding for the purposes of computing the percentage
ownership of any other person. The same shares may be beneficially owned by more than one person. Unless otherwise indicated, the address of record for the owner is c/o Synova Healthcare Group, Inc., 1400 North Providence Road, Suite 6010, Media,
Pennsylvania 19063.



|                                                                 |  |                                                       |     |  |                                                |  
|---------------------------------------------------------------- |  | ----------------------------------------------------- | --- |  | ---------------------------------------------- | -
|Name and Address                                                 |  | Number of Shares of OurCommon StockBeneficially Owned |     |  | Percentage of OurCommon StockBeneficiallyOwned |  
|                                                                 |  |                                                      
|Stephen E. King                                                  |  | 2,057,125                                             | (1) |  | 6.2                                            | %
|                                                                 |  |                                                      
|David J. Harrison                                                |  | 2,056,915                                             | (2) |  | 6.2                                            | %
|                                                                 |  |                                                      
|Patricia Campbell                                                |  | 35,500                                                | (3) |  | *                                              |  
|                                                                 |  |                                                      
|Steven L. Edell, D.O.                                            |  | 137,499                                               | (4) |  | *                                              |  
|                                                                 |  |                                                      
|Jeffrey N. Pelesh                                                |  | 86,250                                                | (5) |  | *                                              |  
|                                                                 |  |                                                      
|Ronald S. Spangler, Ph.D.                                        |  | 141,000                                               | (6) |  | 0.4                                            | %
|                                                                 |  |                                                      
|John M. Suender                                                  |  | 31,500                                                | (7) |  | *                                              |  
|                                                                 |  |                                                      
|George T. Votis 655 Madison Avenue, 24thFloor New York, NY 10021 |  | 13,660,587                                            | (8) |  | 40.3                                           | %



---

|                                                                                        |  |            |          |  |      |  
|--------------------------------------------------------------------------------------- |  | ---------- | -------- |  | ---- | -
|                                                                                        |  |            |          |  |      |  
|                                                                                        |  |           
|Bianchi & Partner AG Friesenbergstrasse 98 CH-8055 Zurich, Switzerland(9)               |  | 2,049,990  | (10)(11) |  | 6.0  | %
|                                                                                        |  |           
|Plainfield Direct LLC 55 Railroad Avenue Greenwich, Connecticut 06830(12)               |  | 10,500,000 | (13)     |  | 24.0 | %
|                                                                                        |  |           
|Brian J. Stark 3600 South Lake Drive St. Francis, Wisconsin 53235                       |  | 3,651,067  | (14)     |  | 9.9  | %
|                                                                                        |  |           
|Michael A. Roth 3600 South Lake Drive St. Francis, Wisconsin 53235                      |  | 3,651,067  | (14)     |  | 9.9  | %
|                                                                                        |  |           
|Ronald S. Dagar 275 Seventh Avenue, Suite 2000 New York, New York 10001(15)             |  | 2,561,612  | (16)     |  | 7.3  | %
|                                                                                        |  |           
|Erwin Speckert Ramistrasse 8, Postfach 659 CH 8024 Zurich, Switzerland(17)              |  | 2,842,806  | (18)     |  | 8.1  | %
|                                                                                        |  |           
|Everest Asset Management AG Ramistrasse 8, Postfach 659 CH 8024 Zurich, Switzerland(17) |  | 2,671,773  | (19)     |  | 7.6  | %
|                                                                                        |  |           
|All directors and executive officersas a group (9 persons)                              |  | 18,327,376 | (20)     |  | 53.0 | %

---

|* | Less than 1%.
|- | -------------



|(1) | Includes (i) an option to purchase 131,250 shares of common stock at an exercise price of $0.0011 per share; (ii) 700 shares of common stock held of record by a member of
Mr. Kings immediate family of which Mr. King shares beneficial ownership; (iii) a senior convertible promissory note which is immediately convertible into 17,500 shares of common stock; (iv) a warrant to purchase 19,250
shares of common stock at an exercise price of $1.00 per share; and (v) 450,000 shares of common stock subject to pledges as collateral for security for two personal loans, for which Mr. King and his spouse are borrowers. In July and
August 2007, Mr. King pledged as collateral to one of these lenders an additional 200,000 shares of common stock.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(2) | Includes (i) an option to purchase 131,250 shares of common stock at an exercise price of $0.0011 per share; (ii) 1,750 shares of common stock held of record by a member
of Mr. Harrisons immediate family of which Mr. Harrison shares beneficial ownership; (iii) a senior convertible promissory note which is immediately convertible into 17,500 shares of common stock; and (iv) a warrant to
purchase 19,250 shares of common stock at an exercise price of $1.00 per share.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(3) | Includes (i) an option to purchase 25,000 shares at an exercise price of $1.82 per share; (ii) a senior convertible promissory note which is immediately convertible into
5,000 shares of common stock; and (iii) a warrant to purchase 5,500 shares of common stock at an exercise price of $1.00 per share.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(4) | Includes a warrant to purchase 16,666 shares of common stock at an exercise price of $2.50 per share. All of these securities are held jointly with Dr. Edells spouse.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(5) | Includes an option to purchase 25,000 shares at an exercise price of $1.82 per share.
|--- | -------------------------------------------------------------------------------------





---

|(6) | Includes (i) exercisable options to purchase an aggregate of 120,000 shares of common stock at an exercise price of $2.78 per share; (ii) a senior convertible promissory
note which is immediately convertible into 10,000 shares of common stock; and (iii) a warrant to purchase 11,000 shares of common stock at an exercise price of $1.00 per share.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(7) | Includes (i) a senior convertible promissory note which is immediately convertible into 15,000 shares of common stock; and (ii) a warrant to purchase 16,500 shares of
common stock at an exercise price of $1.00 per share.
|--- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(8) | Includes (i) 12,696,089 shares of common stock acquired in connection with our merger with Allendale; (ii) the right to vote 333,334 shares of common stock held in escrow
on behalf of Mr. Votis to satisfy certain indemnification obligations in connection with our acquisition of Allendale; (iii) an option to purchase 11,664 shares of common stock at an exercise price of $8.04 per share; (iv) a senior
convertible promissory note which is immediately convertible into 295,000 shares of common stock; and (v) a warrant to purchase 324,500 shares of common stock at an exercise price of $1.00 per share.
|--- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(9) | Gabriel U. Bianchi has sole voting and investment power over the securities held by Bianchi & Partner AG.
|--- | ---------------------------------------------------------------------------------------------------------



|(10) | Includes a senior convertible promissory note which is immediately convertible into 500,000 shares of common stock and a warrant to purchase 550,000 shares of common stock at an
exercise price of $1.00 per share.
|---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(11) | Excludes a warrant to purchase up to an additional 499,980 shares of common stock, which, pursuant to the terms thereof, may not be exercised so long as the holder would
beneficially own more than 4.99% of our common stock either prior to or after giving effect to the exercise. We currently believe that this stockholder owns more than 4.99% of our common stock, and therefore this warrant would not be presently
exercisable. However, if this warrant could be exercised in full, Bianchi & Partner AG would be deemed to beneficially own a total of 2,549,970 shares of common stock, or 7.3%.
|---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(12) | These shares are beneficially owned by each of the following persons, who collectively may be deemed to be a group within the meaning of Rule 13d-5 promulgated under the
Securities Exchange Act of 1934, as amended: Plainfield Direct LLC, Plainfield Special Situations Master Fund Limited, Plainfield Direct Master Fund Limited, Plainfield Asset Management LLC, and Max Holmes. This information was obtained exclusively
from a Schedule 13D filed by such beneficial owners with the SEC on January 22, 2007.
|---- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(13) | Includes a senior convertible promissory note which is immediately convertible into 5,000,000 shares of common stock and a warrant which is immediately exercisable for up to
5,500,000 shares of common stock at an exercise price of $1.00 per share. This information was obtained exclusively from Amendment No. 1 to Schedule 13D, as filed with the SEC on January 24, 2007 by the Plainfield group.
|---- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(14) | Includes an aggregate of 3,651,067 shares of common stock issuable upon conversion of a senior convertible promissory note and the exercise of a warrant. Excludes an aggregate of
6,848,943 shares of common stock issuable upon the conversion of a senior convertible promissory note and the exercise of a warrant, the conversion and exercise of which are subject to a conversion cap and exercise cap that preclude the stockholder
from exercising its conversion or exercise rights to the extent that the stockholder would beneficially own in excess of 9.9% of our common stock after giving effect to such conversion or exercise. If these securities could be exercised in full,
these stockholders would be deemed to beneficially own a total of 10,500,000 shares of common stock, or 24.0%.
|---- | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(15) | Ronald S. Dagar may be deemed to beneficially own securities owned by Bushido Capital Master Fund, LP and Pierce Diversified Strategy Master Fund, LLC, Series BUS.
|---- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(16) | Includes (i) a senior convertible promissory note which is immediately convertible into 1,000,000 shares of common stock; and (ii) a warrant to purchase
up to 1,100,000 shares of common stock at an exercise price of $1.00 per share. Excludes warrants to purchase up to 416,661 shares of common stock at an exercise price of
|---- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---

| | $2.50 per share which, pursuant to the terms thereof, may not be exercised so long as the holder would beneficially own more than 4.99% of our common stock
either prior to or after giving effect to the exercise. We currently believe that this stockholder owns more than 4.99% of our common stock, and therefore these warrants would not be presently exercisable. However, if these warrants could be
exercised in full, the stockholder would be deemed to beneficially own a total of 2,978,273 shares of common stock, or 8.3%.
| | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(17) | Erwin Speckert controls Everest Asset Management AG and thus beneficially owns all securities that are beneficially owned by this entity. We believe that this entity has voting or
investment control over securities held by other individuals and entities pursuant to the terms of an asset management agreement.
|---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(18) | Includes (i) 1,966,736 shares of common stock underlying senior convertible promissory notes and related common stock purchase warrants held by Everest Asset Management AG,
(ii) an aggregate of 571,773 shares of common stock owned of record by clients of Everest over which Everest may have voting and investment control; (iii) 202,865 shares of common stock owned directly by Mr. Speckert; and
(iv) 101,432 shares of common stock owned of record by Mr. Speckerts spouse. Excludes (i) 133,264 shares underlying senior convertible promissory notes and related common stock purchase warrants which, pursuant to the terms
thereof, may not be converted or exercised so long as the holder would beneficially own after such conversion or exercise more than 9.9% of our common stock and (ii) warrants to purchase in the aggregate up to 712,000 shares of common stock at
an exercise price of $2.50 per share which, pursuant to the terms thereof, may not be exercised so long as the holder would beneficially own more than 4.99% of our common stock either prior to or after giving effect to the exercise. We currently
believe that this stockholder owns more than 9.9% of our common stock, and therefore these securities would not be presently exercisable. However, if these notes and warrants could be exercised in full, the stockholder would be deemed to
beneficially own a total 3,688,070 shares of common stock, or 10.2%.
|---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(19) | Includes (i) 1,000,000 shares of common stock underlying our senior notes and (ii) a warrant to purchase up to 1,100,000 shares of common stock at an exercise price of
$1.00 per share. Excludes warrants to purchase in the aggregate up to 472,000 shares of common stock at an exercise price of $2.50 per share which, pursuant to the terms thereof, may not be exercised so long as the holder would beneficially own more
than 4.99% of our common stock either prior to or after giving effect to the exercise. We currently believe that this stockholder owns more than 4.99% of our common stock, and therefore these warrants would not be presently exercisable. However, if
these warrants could be exercised in full, the stockholder would be deemed to beneficially own 3,143,773 shares of common stock, or 8.8%.
|---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



|(20) | Includes (i) all shares, options and warrants disclosed in footnotes (1) through (8) above; (ii) a senior convertible promissory note which is immediately
convertible into 10,000 shares of common stock held by one of our executive officers not named in the table above; (iii) a warrant to purchase 11,000 shares of common stock at an exercise price of $1.00 per share held by one of our executive
officers not named in the table above; (iv) an option to purchase 50,000 shares of common stock at an exercise price of $2.67 per share held by one of our executive officers not named in the table above; and (v) the vested portion (50,000
shares) of an option to purchase 200,000 shares of common stock at an exercise price of $2.50 per share held by one of our executive officers not named in the table above.
|---- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------



---

Related Stockholder Matters

The following table sets forth information with respect to our equity compensation plans as of December 31, 2006.

EQUITY
COMPENSATION PLAN INFORMATION

AS OF DECEMBER 31, 2006



|                                                               |  |                                                                                            |        |  |                                                                             |      |        |                                                                                                                                          |         |    
|-------------------------------------------------------------- |  | ------------------------------------------------------------------------------------------ | ------ |  | --------------------------------------------------------------------------- | ---- | ------ | ---------------------------------------------------------------------------------------------------------------------------------------- | ------- | ---
|Plan Category                                                  |  | Number
ofsecurities to beissued upon exerciseof outstandingoptions, warrantsand rights (a) |        |  | Weighted-averageexercise price ofoutstandingoptions, warrantsand rights (b) |      |        | Number of securitiesremaining availablefor future
issuanceunder equitycompensation plans(excluding securitiesreflected in column(a)) (c) |        
|                                                               |  |                                                                                            |       
|Equity compensation plans approved by security holders         |  | 749,000                                                                                    | (1)    |  | $                                                                           | 2.56 | (1)    |                                                                                                                                          | 706,000 |    
|                                                               |  |                                                                                            |       
|Equity compensation plans not approved by security holders (2) |  | 1,128,587                                                                                  | (3)    |  | $                                                                           | 0.64 | (3)    |                                                                                                                                          | 280,000 | (4)
|                                                               |  |                                                                                            |       
|Total                                                          |  | 1,922,587                                                                                  | (1)(3) |  | $                                                                           | 1.43 | (1)(3) |                                                                                                                                          | 986,000 |    

---

|(1) | All of these options were issued under our 2005 Equity Incentive Plan, which was approved by our stockholders on May 27, 2005 effective as of April 26, 2005.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------

|(2) | Amounts included in this row include individual securities compensation arrangements entered into with both employees and non-employees, including directors, consultants, advisors,
vendors, customers, suppliers and lenders.
|--- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(3) | As part of our merger with Synova Healthcare, Inc., we assumed outstanding options, warrants and other rights to purchase 562,045 shares of our common stock with an aggregate
weighted-average exercise price of $0.06. The issuance of these options, warrants and other rights were not approved by our stockholders.
|--- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(4) | This amount represents shares of our common stock that are subject to future awards under our Consultant Stock Compensation Plan, pursuant to which an aggregate of 300,000 shares of
common stock have been reserved for issuance.
|--- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Descriptions of the material features of our equity compensation plans and
individual compensation arrangements that have not been approved by our stockholders are set forth in the notes to our consolidated financial statements on pages F-17 through F-18 and are incorporated herein by reference.

Consultant Stock Compensation Plan

On
December 22, 2005, we adopted the Synova Healthcare Group, Inc. Consultant Stock Compensation Plan. A total of 300,000 shares of common stock is authorized for issuance under the consultant plan. This plan provides compensation in the form of
shares of common stock to eligible consultants and advisors who have provided bona fide services to us or our subsidiaries, other than services rendered in connection with the offer and sale of securities in a capital raising transaction or services
that promote or maintain a market price for the our securities. The shares of stock issuable under the consultant plan have been registered on a Form S-8 registration statement. Shares may be granted only to consultants and advisors who are retained
by us or by our subsidiaries and who are eligible to receive shares registered on Form S-8. As of December 31, 2006, we had issued 20,000 shares of common stock under the consultant plan.

Item 13.Exhibits.



|            |  |                                                                                                                             
|----------- |  | ----------------------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                                 
|            | 
|31.1        |  | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                         
|            | 
|31.2        |  | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                         
|            | 
|32.1        |  | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (28 U.S.C. Section 1350).
|            | 
|32.2        |  | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (28 U.S.C. Section 1350).





---

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.



| |  |  |  |                               |  |                                                     
| |  |  |  | ----------------------------- |  | ----------------------------------------------------
| |  |  |  | SYNOVA HEALTHCARE GROUP, INC.
| |  |  | 
| |  |  |  | By:                           |  | /s/    Stephen E. King                              
| |  |  |  |                               |  | Stephen E. King Chairman and Chief Executive Officer

Date: November 7, 2007

In accordance with the Exchange Act, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.



|                       |  |  |  |     |  |                                                                                       
|---------------------- |  |  |  | --- |  | --------------------------------------------------------------------------------------
|                       |  |  | 
|Date: November 7, 2007 |  |  |  | By: |  | /s/    Stephen E. King                                                                
|                       |  |  |  |     |  | Stephen E. King Chairman and Chief Executive Officer (Principal Executive Officer)    
|                       |  |  | 
|Date: November 7, 2007 |  |  |  | By: |  | /s/    David J. Harrison                                                              
|                       |  |  |  |     |  | David J. Harrison President, Chief Operating Officer and Director                     
|                       |  |  | 
|Date: November 7, 2007 |  |  |  | By: |  | /s/    Robert L. Edwards                                                              
|                       |  |  |  |     |  | Robert L. Edwards Chief Financial Officer (Principal Financial and Accounting Officer)
|                       |  |  | 
|Date: November 7, 2007 |  |  |  | By: |  | /s/    Steven L. Edell, D.O.                                                          
|                       |  |  |  |     |  | Steven L. Edell, D.O. Director                                                        
|                       |  |  | 
|Date: November 7, 2007 |  |  |  | By: |  | /s/    Alan B. Levin                                                                  
|                       |  |  |  |     |  | Alan B. Levin Director                                                                



---

EXHIBIT INDEX



|            |  |                                                                                                                             
|----------- |  | ----------------------------------------------------------------------------------------------------------------------------
|Exhibit No. |  | Description                                                                                                                 
|            | 
|31.1        |  | Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                         
|            | 
|31.2        |  | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.                         
|            | 
|32.1        |  | Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (28 U.S.C. Section 1350).
|            | 
|32.2        |  | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (28 U.S.C. Section 1350).